Charting a path to sustainable science
100% biodegradable products to eliminate reliance on animal resources.
Why start with the HAI assay ?
Traditional HAI assay rely on animal red blood cells, creating major obstacles for research.
- Difficulty in ensuring inter-batch and inter-laboratory homogeneity, which compromises reproducibility.
- Strong dependence on the quality and origin of erythrocytes.
- Sensitivity to variations in storage, age and manipulation of cells.
Variability Issues
Operational Challenges
- Delicate handling and limited lifespan.
- Ethical constraints linked to the use of animal resources.
- Vulnerable supply chains, particularly in a pandemic context.
Our Technology in Development
The HAI assay marks the start of our technological revolution. This is our first concrete application to transform the vaccine analysis industry.
Current Phase
Currently in the pre-launch phase, Varion Biotech will begin its activities with intensive development of its solution in the laboratory.
Future Vision
Expand our technology to other applications and other pathogens.
Immediat Objective
Eliminate immedia variabilities caused by animal-derived red blood cells in testing.
Our Synthetic Solution
To provide cconsistent and reliable results while eliminating the source of variability.
Consistent Performance
Eliminating lot-to-lot variability, ensuring reproducible results across all testing environments.
Enhanced Stability
Extended shelf life and improved storage conditions reducing operational complexity.
An approach with no animal sources, aligned with modern ethical and regulatory standards while being mindful of environmental respect.
Ethical and Sustainable
Our First Challenge:
Revolutionizing the HAI test
(Hemagglutination Inhibition assay)
Replace animal-derived red cells with a synthetic derivative.
Innovation in Development
Impact on Vaccine Development
Our technology addresses the critical needs of the vaccine industry, enabling more reliable and efficient testing protocols.
Unified testing standards across different laboratories and geographic regions.
Global Standardization
Faster vaccine development thanks to more reliable and less variable test results.
Accelerated Development
Reduced operational costs through improved stability and supply chain independence.
Economic Efficiency
Our Objective
From development to commercialization of our product for the HAI test.
2025-2026
Optimization et Validation
(Pre) Launch
Commercialization
2026-2028
2028-2030
2031
Development
Innovations
Charting a path to sustainable science
100% biodegradable products to eliminate reliance on animal resources.
Our Technology in Development
The HAI assay marks the start of our technological revolution. This is our first concrete application to transform the vaccine analysis industry.
Current Phase
Currently in the pre-launch phase, Varion Biotech will begin its activities with intensive development of its solution in the laboratory.
Future Vision
Expand our technology to other applications and other pathogens.
Immediat Objective
Eliminate immedia variabilities caused by animal-derived red blood cells in testing.
Impact on Vaccine Development
Our technology addresses the critical needs of the vaccine industry, enabling more reliable and efficient testing protocols.
Faster vaccine development thanks to more reliable and less variable test results.
Accelerated Development
Unified testing standards across different laboratories and geographic regions.
Global Standardization
Reduced operational costs through improved stability and supply chain independence.
Economic Efficiency
Our Synthetic Solution
To provide consistent and reliable results while eliminating the source of variability.
Consistent Performance
Eliminating lot-to-lot variability, ensuring reproducible results across all testing environments.
Enhanced Stability
Extended shelf life and improved storage conditions reducing operational complexity.
An approach with no animal sources, aligned with modern ethical and regulatory standards while being mindful of environmental respect.
Ethical and Sustainable
Why start with the HAI assay?
Traditional HAI assay rely on animal red blood cells, creating major obstacles for research.
- Difficulty in ensuring inter-batch and inter-laboratory homogeneity, which compromises reproducibility.
- Strong dependence on the quality and origin of erythrocytes.
- Sensitivity to variations in storage, age and manipulation of cells.
Variability Issues
Operational Challenges
- Delicate handling and limited lifespan.
- Ethical constraints linked to the use of animal resources.
- Vulnerable supply chains, particularly in a pandemic context.
Innovations
Our First Challenge:
Revolutionizing the HAI test
(Hemagglutination Inhibition assay)
Innovation in Development
Replacing animal-derived red blood cells with a synthetic derivative.
Our Objective
From development to commercialization of our product for the HAI test.
2025-2026
Optimization et Validation
(Pre) Launch
Commercialization
2026-2028
2029-2030
2031
Development